89Zr-trastuzumab-PET gauges treatment response in gastric cancer

04/24/2013 | HealthImaging.com

PET imaging with 89Zr-trastuzumab is effective in monitoring treatment response in animals with human epidermal growth factor receptor 2-positive stomach cancer being treated with afatinib, according to findings from a study published in The Journal of Nuclear Medicine. Researchers said 89Zr-trastuzumab-PET performed better than 18F-FDG-PET in determining drug uptake. There is a need for human studies to validate the efficacy of the method in monitoring treatment response, researchers added.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA